Executive Employment Sample Contracts

Horizon Therapeutics Public Ltd Co – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA USA, INC. AND (May 8th, 2019)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045, (hereinafter referred to together as the “Company”) and Dr. Jeffery Kent (hereinafter referred as to the “Executive”).The terms of this Agreement shall be effective commencing May 1, 2019 (the “Effective Date”).

Clearside Biomedical, Inc. – April 16, 2019 George Lasezkay XXXXX Re: Offer of Executive Employment Dear George, (April 17th, 2019)

Clearside Biomedical, Inc. (the “Company”), is pleased to offer you limited term employment on the terms set forth in this Offer of Executive Employment (the “Agreement”).  Subject to your execution of this Agreement as provided below, effective as of April 7, 2019 (the “Effective Date”), you will be employed in the position of Interim Chief Executive Officer (“Interim CEO”) on the following terms.

Horizon Pharma Plc – AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND GEOFF CURTIS (February 27th, 2019)

This Amended and Restated Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045, (hereinafter referred to together as the “Company”) and Geoff Curtis (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing August 1, 2018 (the “Effective Date”).

Polarityte, Inc. – EXECUTIVE EMPLOYMENT AGREEMENT (September 14th, 2018)

This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 12th day of May, 2018 by and between PolarityTE, Inc., a Delaware corporation headquartered at 1960 S 4250 W, Salt Lake City, UT 84104 (“Parent”) and Paul Mann, an individual (“Executive”). As used herein, the “Effective Date” of this Agreement shall mean the date as written above and signed below.

Synchronoss Technologies Inc – May 5, 2017 Daniel Rizer [Delivered Electronically] Re: Executive Employment Letter Dear Daniel, (August 9th, 2018)

On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to confirm your role on the Synchronoss Executive Team. In your role, your title will be Executive Vice President, Business Development, and you will report directly to the Company’s CEO, Stephen Waldis.

Synchronoss Technologies Inc – May 8, 2017 Chris Putnam [Delivered Electronically] Re: Executive Employment Letter Dear Chris, (August 9th, 2018)

On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to formally confirm your role on the Synchronoss Executive Team. Your title will remain Executive Vice President, Sales, and you will report directly to the Company’s President & COO, Bob Garcia.

Synchronoss Technologies Inc – TIER ONE EXECUTIVE EMPLOYMENT PLAN (August 9th, 2018)

In addition to the terms of your offer letter or executive employment letter (“Offer Letter”) with Synchronoss Technologies, Inc., a Delaware corporation (the “Company”), the employment of each Tier One Executive (“Executive”) shall be governed by the terms and conditions set forth in this Tier One Executive Employment Plan (the “Plan”).

Synchronoss Technologies Inc – May 8, 2017 Chris Putnam [Delivered Electronically] Re: Executive Employment Letter Dear Chris, On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to formally confirm your role on the Synchronoss Executive Team. Your title will remain Executive Vice President, Sales, and you will report directly to the Company’s President & COO, Bob Garcia. Your annual base salary will remain at $340,000, and you will still be eligible for a discretionary annual target bonus of 120% of your base salary based upon the achievement of certain company objectives to be established and approved (July 9th, 2018)
Synchronoss Technologies Inc – May 5, 2017 Daniel Rizer [Delivered Electronically] Re: Executive Employment Letter Dear Daniel, On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to confirm your role on the Synchronoss Executive Team. In your role, your title will be Executive Vice President, Business Development, and you will report directly to the Company’s CEO, Stephen Waldis. Your annual base salary for this position will remain at $420,000, and you will also be eligible for a discretionary annual target bonus of 80% of your base salary based upon the achievement of certain company objectives to be (July 9th, 2018)
Synchronoss Technologies Inc – May 8, 2017 Chris Putnam [Delivered Electronically] Re: Executive Employment Letter Dear Chris, On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to formally confirm your role on the Synchronoss Executive Team. Your title will remain Executive Vice President, Sales, and you will report directly to the Company’s President & COO, Bob Garcia. Your annual base salary will remain at $340,000, and you will still be eligible for a discretionary annual target bonus of 120% of your base salary based upon the achievement of certain company objectives to be established and approved (July 9th, 2018)
Synchronoss Technologies Inc – May 8, 2017 Chris Putnam [Delivered Electronically] Re: Executive Employment Letter Dear Chris, On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to formally confirm your role on the Synchronoss Executive Team. Your title will remain Executive Vice President, Sales, and you will report directly to the Company’s President & COO, Bob Garcia. Your annual base salary will remain at $340,000, and you will still be eligible for a discretionary annual target bonus of 120% of your base salary based upon the achievement of certain company objectives to be established and approved (July 2nd, 2018)
Synchronoss Technologies Inc – May 8, 2017 Chris Putnam [Delivered Electronically] Re: Executive Employment Letter Dear Chris, On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to formally confirm your role on the Synchronoss Executive Team. Your title will remain Executive Vice President, Sales, and you will report directly to the Company’s President & COO, Bob Garcia. Your annual base salary will remain at $340,000, and you will still be eligible for a discretionary annual target bonus of 120% of your base salary based upon the achievement of certain company objectives to be established and approved (July 2nd, 2018)
Synchronoss Technologies Inc – May 5, 2017 Daniel Rizer [Delivered Electronically] Re: Executive Employment Letter Dear Daniel, On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to confirm your role on the Synchronoss Executive Team. In your role, your title will be Executive Vice President, Business Development, and you will report directly to the Company’s CEO, Stephen Waldis. Your annual base salary for this position will remain at $420,000, and you will also be eligible for a discretionary annual target bonus of 80% of your base salary based upon the achievement of certain company objectives to be (July 2nd, 2018)
Synchronoss Technologies Inc – May 8, 2017 Chris Putnam [Delivered Electronically] Re: Executive Employment Letter Dear Chris, On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to formally confirm your role on the Synchronoss Executive Team. Your title will remain Executive Vice President, Sales, and you will report directly to the Company’s President & COO, Bob Garcia. Your annual base salary will remain at $340,000, and you will still be eligible for a discretionary annual target bonus of 120% of your base salary based upon the achievement of certain company objectives to be established and approved (July 2nd, 2018)
Synchronoss Technologies Inc – May 5, 2017 Daniel Rizer [Delivered Electronically] Re: Executive Employment Letter Dear Daniel, On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to confirm your role on the Synchronoss Executive Team. In your role, your title will be Executive Vice President, Business Development, and you will report directly to the Company’s CEO, Stephen Waldis. Your annual base salary for this position will remain at $420,000, and you will also be eligible for a discretionary annual target bonus of 80% of your base salary based upon the achievement of certain company objectives to be (July 2nd, 2018)
Synchronoss Technologies Inc – May 5, 2017 Daniel Rizer [Delivered Electronically] Re: Executive Employment Letter Dear Daniel, On behalf of Synchronoss Technologies, Inc. (the Company), I am pleased to confirm your role on the Synchronoss Executive Team. In your role, your title will be Executive Vice President, Business Development, and you will report directly to the Company’s CEO, Stephen Waldis. Your annual base salary for this position will remain at $420,000, and you will also be eligible for a discretionary annual target bonus of 80% of your base salary based upon the achievement of certain company objectives to be (July 2nd, 2018)
Horizon Pharma Plc – AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND VIKRAM KARNANI (May 9th, 2018)

This Amended and Restated Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045, (hereinafter referred to together as the “Company”) and Vikram Karnani (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing March 1, 2018 (the “Effective Date”).

Horizon Pharma Plc – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND SHAO-LEE LIN (February 28th, 2018)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Rd, Lake Forest IL 60045, (hereinafter referred to together as the “Company”) and Shao-Lee Lin (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing January 4, 2018 (the “Effective Date”).

Horizon Pharma Plc – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND MICHAEL DESJARDIN (February 28th, 2018)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045 (hereinafter referred to together as the “Company”) and Michael DesJardin (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing February 16, 2017 (the “Effective Date”). Certain capitalized terms used in this Agreement have the meanings as set forth in Section 4.5.

Maximus Inc – EXECUTIVE EMPLOYMENT, NON-COMPETE (January 16th, 2018)

THIS EXECUTIVE EMPLOYMENT, NON-COMPETE AND CONFIDENTIALITY AGREEMENT (this "Agreement"), is entered into as of the date set forth on the signature page (the “Execution Date”) by and between Bruce L. Caswell (the "Executive") and MAXIMUS, Inc., a Virginia corporation with its principal place of business in Reston, Virginia (the "Corporation") with reference to the following:

Horizon Pharma Plc – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND ERIC MOSBROOKER (November 6th, 2017)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Rd., Lake Forest, IL 60045, (hereinafter referred to together as the “Company”) and Eric Mosbrooker (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing August 21, 2017 (the “Effective Date”).

Horizon Pharma Plc – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND IRINA KONSTANTINOVSY (November 6th, 2017)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Rd, Lake Forest IL 60045, (hereinafter referred to together as the “Company”) and Irina Konstantinovsky (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing September 11, 2017 (the “Effective Date”).

Horizon Pharma Plc – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND VIKRAM KARNANI (August 7th, 2017)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045, (hereinafter referred to together as the “Company”) and Vikram Karnani (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing February 1, 2017 (the “Effective Date”).

IASO BioMed, Inc. – EXECUTIVE EMPLOYMENT AND NON-COMPETE AGREEMENT (March 24th, 2017)

THIS AGREEMENT (this “Agreement”) is dated this 1st day of March, 2017 (the “Effective Date”), by and between IASO BioMed, Inc., a Colorado corporation with offices at 7315 East Peakview Ave., Centennial, Colorado 80111 (the “Company”), and Richard M. Schell, (“Executive”).

IASO BioMed, Inc. – EXECUTIVE EMPLOYMENT AND NON-COMPETE AGREEMENT (March 24th, 2017)

THIS AGREEMENT (this “Agreement”) is dated this 1st day of March, 2017 (the “Effective Date”), by and between IASO BioMed, Inc., a Colorado corporation with offices at 7315 East Peakview Ave., Centennial, Colorado 80111 (the “Company”), and Duane Knight, (“Executive”).

Horizon Pharma Plc – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND DAVID A. HAPPEL (February 27th, 2017)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045 (hereinafter referred to together as the “Company”) and David A. Happel (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing October 25, 2016 (the “Effective Date”).

WisdomTree Investments, Inc. – Appendix A to Executive Employment Letter dated December 22, 2016 Executive: Luciano Siracusano III (December 23rd, 2016)
WisdomTree Investments, Inc. – Appendix A to Executive Employment Letter dated December 22, 2016 Executive: Amit Muni (December 23rd, 2016)
WisdomTree Investments, Inc. – Appendix A to Executive Employment Letter dated December 22, 2016 Executive: Gregory Barton (December 23rd, 2016)
WisdomTree Investments, Inc. – Appendix A to Executive Employment Letter dated December 22, 2016 Executive: Peter M. Ziemba (December 23rd, 2016)
WisdomTree Investments, Inc. – Appendix A to Executive Employment Letter dated December 22, 2016 Executive: Jonathan Steinberg (December 23rd, 2016)
Horizon Pharma Plc – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND DAVID A. HAPPEL (November 7th, 2016)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon

Mylan N.V. – EXECUTIVE EMPLOYMENT AGREEMENT (August 9th, 2016)

This Executive Employment Agreement (the “Agreement”) is dated as of June 6, 2016, by and between Mylan Inc. (the “Company” or “Mylan”) and Kenneth S. Parks (“Executive”).

Horizon Pharma Plc – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND TIMOTHY J. ACKERMAN (May 9th, 2016)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045, (hereinafter referred to together as the “Company”) and Timothy J. Ackerman (hereinafter referred as to the “Executive”).   The terms of this Agreement shall be effective commencing February 26, 2016 (the “Effective Date”).

Horizon Pharma Plc – EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND GEOFF CURTIS (May 9th, 2016)

This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045, (hereinafter referred to together as the “Company”) and Geoff Curtis (hereinafter referred as to the “Executive”).   The terms of this Agreement shall be effective commencing February 26, 2016 (the “Effective Date”).